Patents Assigned to Novartis Vaccines and Diagnostics, Inc.
  • Publication number: 20180221446
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS: 1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: September 8, 2017
    Publication date: August 9, 2018
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Patent number: 9926371
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: March 27, 2018
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS, INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Patent number: 9730997
    Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: August 15, 2017
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
  • Publication number: 20170152311
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: November 9, 2016
    Publication date: June 1, 2017
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Publication number: 20170081416
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Application
    Filed: August 19, 2016
    Publication date: March 23, 2017
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Li Long, Mohammad Luqman (deceased), Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
  • Patent number: 9598469
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: March 21, 2017
    Assignees: Novartis Vaccines and Diagnostics, Inc., University of Stellenbosch
    Inventors: Jan Zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse Van Rensberg, Thomas J. Scriba
  • Patent number: 9522186
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: December 20, 2016
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Patent number: 9428739
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: August 30, 2016
    Assignee: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • Publication number: 20160120943
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: September 28, 2015
    Publication date: May 5, 2016
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Patent number: 9255126
    Abstract: Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: February 9, 2016
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang
  • Publication number: 20160015809
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: June 3, 2015
    Publication date: January 21, 2016
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Publication number: 20150299269
    Abstract: Influenza viruses have traditionally been administered by intramuscular injection. The invention is based on the idea of using alternative routes of delivery for influenza vaccines, more specifically routes that do not require as large a dose of antigen. Delivery of influenza antigen to the Langerhans cells is the route of choice according to the invention. This route has been found to be particularly useful for vaccinating patients who are naïve to influenza virus (i.e. have not previously mounted an immune response to an influenza virus), which means that it is advantageous for immunising young children.
    Type: Application
    Filed: March 30, 2015
    Publication date: October 22, 2015
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventor: Derek O'HAGAN
  • Patent number: 9079956
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 14, 2015
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Patent number: 9024001
    Abstract: Provided herein are modified, functional 5? amplification sequences that are defective packaging signals. Also provided are compositions and methods comprising these modified 5? amplification sequences.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: May 5, 2015
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Zequn Tang, Silvia Perri, John Polo
  • Publication number: 20150031743
    Abstract: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.
    Type: Application
    Filed: July 5, 2014
    Publication date: January 29, 2015
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Timothy S. BURKOTH, Ann B. JEFFERSON, Christoph REINHARD, Ronald N ZUCKERMANN
  • Publication number: 20140349932
    Abstract: The present invention provides a unit dose composition comprising 0.2 ?g/kg to 48 ?g/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.
    Type: Application
    Filed: June 23, 2014
    Publication date: November 27, 2014
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventor: Martha Jo Whitehouse
  • Publication number: 20140322700
    Abstract: The invention provides a method for determining the concentration of virus particles and/or virus antigens in a sample. In particular, the invention relates to determining the concentration of influenza virus particles/influenza virus antigens in a sample. The invention further relates to the use of an ion-exchange matrix for the determination of the concentration of virus particles and/or virus antigens in a sample.
    Type: Application
    Filed: May 21, 2014
    Publication date: October 30, 2014
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Holger KOST
  • Publication number: 20140242071
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: February 3, 2014
    Publication date: August 28, 2014
    Applicants: XOMA TECHNOLOGY LTD., NOVARTIS VACCINES AND DIAGNOSTICS INC.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Publication number: 20140220060
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Application
    Filed: December 26, 2013
    Publication date: August 7, 2014
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Jan ZUR MEGEDE, Susan BARNETT, Ying LIAN, Susan ENGELBRECHT, Estrelita Janse VAN RENSBERG, Thomas J. SCRIBA
  • Patent number: RE45137
    Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: September 16, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Nicholas Valiante